Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |
PMID | |
Authors | Yasir Elamin, Sinead Toomey, Aoife Carr, Kathy Gately, Shereen Rafee, William Grogan, Patrick G. Morris, Oscar S. Breathnach, John Crown, Kenneth O'Byrne, Bryan Hennessy |
Title | Protein tyrosine phosphatase non receptor 11 (PTPN11/Shp2) as a driver oncogene and a novel therapeutic target in non-small cell lung cancer (NSCLC) |
Journal | JCO |
Vol | |
Issue | |
Date | |
URL | http://meetinglibrary.asco.org/content/147146-156 |
Abstract Text | J Clin Oncol 33, 2015 (suppl; abstr 11077) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|---|---|---|---|---|
PTPN11 | A72D | missense | gain of function - predicted | PTPN11 A72D lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). A72D is predicted to confer a gain of function to the Ptpn11 protein as demonstrated by increased phosphatase activity of Ptpn11 and activation of the MAPK and PI3K signaling pathways (J Clin Oncol 32, 2014 (suppl; abstr e22174)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTPN11 act mut | lung non-small cell carcinoma | sensitive | Refametinib | Preclinical | Actionable | In a preclinical study, Refametinib (BAY86-9766) inhibited growth of non-small cell lung cancer cells harboring activating PTPN11 mutations in culture (J Clin Oncol 33, 2015(Suppl; abstr 11077)). | detail... |